Snapshot from Jul 19, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Erasca securities fraud class action
Regulatory securities fraud

Erasca securities fraud class action

Analysis based on 7 articles · First reported Jun 29, 2026 · Last updated Jul 10, 2026

Sentiment
-60
Attention
3
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

Erasca's stock price fell sharply by over 50% in two days following the disclosure of patent allegations and a patient death. The securities fraud lawsuits may result in financial penalties and further reputational damage for Erasca.

Biotechnology Pharmaceuticals
Event Summary

Multiple law firms have filed securities fraud class action lawsuits against Erasca (Nasdaq: ERAS) on behalf of investors who purchased Erasca common stock between January 14, 2025 and April 26, 2026. The lawsuits allege that Erasca made materially false and misleading statements regarding its drug candidate ERAS-0015, including improper comparisons to Revolution Medicines' drug RMC-6236 and failure to disclose risks of patent infringement and trade secret misappropriation. On April 27, 2026, Erasca disclosed a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation, causing its stock to fall 10.9%. The same day, Erasca reported a patient death in a Phase 1 trial of ERAS-0015, leading to an additional 48.3% stock drop. The lead plaintiff deadline is August 10, 2026.

Key Actions
100 Erasca made false statements
100 Erasca reported preliminary clinical data
100 Revolution Medicines sent letter alleging infringement Erasca
80 Glancy Prongay & Murray filed class action lawsuit Erasca
80 The Law Offices of Frank R. Cruz filed securities fraud class action Erasca
Entities Involved
stock
Erasca
Erasca is the defendant in securities fraud class actions; its stock price plummeted after disclosing patent infringement allegations and a patient death in a clinical trial.
Importance 100.0 Sentiment -80.0
stock
Revolution Medicines
Revolution Medicines alleged that Erasca's drug candidate infringes its patent and involves trade secret misappropriation; it is a key complainant in the event.
Importance 70.0 Sentiment 20.0
priv
Glancy Prongay & Murray
This law firm filed a securities fraud class action against Erasca on behalf of investors.
Importance 30.0 Sentiment 0.0
priv
The Law Offices of Frank R. Cruz
This law firm filed a securities fraud class action against Erasca on behalf of investors.
Importance 30.0 Sentiment 0.0
exch
Nasdaq
Erasca is listed on Nasdaq under ticker ERAS; the exchange is not directly impacted by the event.
Importance 10.0 Sentiment 0.0
Relationships
Erasca competitor ↔ Revolution Medicines Erasca is a clinical-stage oncology company that directly competes with Revolution Medicines in developing pan-RAS molec
Glancy Prongay & Murray competitor ↔ The Law Offices of Frank R. Cruz Glancy Prongay & Murray is a prominent plaintiff-side securities litigation firm that frequently co-counsels and compete
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.